New drug cocktail targets hard-to-treat ovarian cancer in early trial
NCT ID NCT07311577
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 study is testing a combination of three drugs (disitamab vedotin, carboplatin, and bevacizumab) as first treatment and ongoing therapy for women with a specific type of advanced ovarian cancer that has a protein called HER2 and lacks a repair deficiency (HRD-negative). The goal is to see if this combo can shrink tumors and delay cancer growth. About 43 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Disitamab vedotin, carboplatin, and bevacizumab
- What this could lead to
- If successful, this could offer a new first-line treatment option for a hard-to-treat form of ovarian cancer, potentially delaying disease progression.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 43 participants, so results may not apply to all patients. The drug combination may cause side effects and may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Cancer Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210000, China
-
Jiangsu Cancer Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.